Neoleukin Therapeutics

Neoleukin Therapeutics: Lead program NL-201: is a dual-acting IL-2 and IL-15 agonist immunotherapy for cancer, designed to improve tolerability and activity by eliminating the alpha receptor binding interface (IND completed 4Q20). First de novo protein therapeutic ever created.
Healthcare/Drug Manufacturers
Based in...
US - Pacific
Clinical Stage
Pre-Clinical Stage
Disease Space
Allergy, Autoimmune, Immuno-Oncology, Infectious Disease, Oncology
Public, USA
Market Cap
500MM - 1B
1616 Eastlake Avenue E
Suit 360
Seattle, WA 98109
United States

Company Participants at Solebury Trout Virtual Management Access Event - 1x1 conference calls

  • Jonathan G. Drachman, CEO

Top 10 Holders of Neoleukin Therapeutics, Inc

Institution OS (%) Position Mkt Val ($MM) Source Filing Date
Redmile Group LLC 8.50 4,131,869 49.09 13F 12/31/20
Baker Bros. Advisors LP 7.86 3,821,740 45.40 13F 12/31/20
Ecor1 Capital LLC 6.42 3,122,704 37.10 Stakes 12/31/20
Pictet Asset Management Ltd. 4.16 2,024,560 24.05 13F 12/31/20
BlackRock Fund Advisors 3.21 1,561,383 18.55 13F 12/31/20
Boxer Capital LLC 3.09 1,501,058 17.83 13F 12/31/20
Opaleye Management, Inc. 2.85 1,386,300 16.47 13F 12/31/20
Point72 Asset Management LP (Old) 2.46 1,195,725 14.21 13F 12/31/20
State Street Corp. 2.42 1,177,350 13.99 13F 12/31/20
The Vanguard Group, Inc. 2.41 1,170,391 13.90 Funds 1/31/21
Ownership data is sourced through FactSet.

Stock Market Data

Data is being loaded...
Data is being loaded...
Data is being loaded...
Data is being loaded...
Market Data copyright © 2021 QuoteMedia. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges). RT=Real-Time, RTB=Real-Time BATS BZX Price/Quote; not sourced from all markets, RTN=Real-Time NASDAQ Basic+ Price/Quote; not sourced from all markets, EOD=End of Day, PD=Previous Day. Market Data powered by QuoteMedia. Terms of Use.